Peptoids Inhibiting Amyloid-Beta Aggregation in Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) are ineffective in stopping or slowing the progression of amyloid-β protein aggregation and plaque formation in the brain, which leads to neuronal loss and cognitive decline, with no viable therapeutic options available.
Innovation Solution
Development of peptoids with a specific formula (H—(NRCH2CO)3—(NACH2CO)2—(NXCH2CO)1—(NACH2CO)2—NH2) that inhibit or reverse amyloid-β aggregation, capable of interacting with Aβ to block aggregation or reverse existing plaques, potentially slowing or halting AD progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules and peptides are used to prevent Aβ aggregation, then some compounds show promise in vitro, but no viable therapeutic treatment is achieved
Solution Approach 1:
The patent modifies the chemical structure parameters of traditional peptides by replacing the peptide backbone with a peptoid backbone (N-substituted glycine units) while maintaining side chain functionality. This structural parameter change confers protease resistance and improved stability, transforming compounds that showed promise in vitro into viable therapeutic candidates that can withstand physiological degradation.
Solution Approach 2:
The invention creates composite molecular structures combining the stable peptoid backbone with functionally active side chains that mimic natural peptide sequences known to inhibit Aβ aggregation. This composite approach merges the structural stability of peptoids with the biological activity of peptide-based inhibitors, achieving both reliability and therapeutic effectiveness.
2Reliability
If Aβ aggregation is allowed to proceed, then plaques form and nerve cells are lost, but current treatments cannot stop or significantly slow progression
Solution Approach 1:
The peptoid compounds are designed to autonomously bind to Aβ monomers and oligomers, preventing their self-aggregation into plaques without requiring complex delivery systems or activation mechanisms. The molecules self-administer their therapeutic function through direct interaction with the pathogenic protein, simplifying treatment availability while maintaining reliable disease progression control.
Solution Approach 2:
The peptoids act as intermediary molecules that mediate between the harmful Aβ aggregation process and the desired therapeutic outcome. By inserting themselves into the aggregation pathway and forming stable complexes with Aβ, they intercept the pathological process and redirect it toward non-toxic outcomes, making treatment available and effective.
3Reliability
If peptides are used to inhibit Aβ aggregation, then aggregation inhibition may be achieved, but protease degradation limits therapeutic viability
Solution Approach 1:
The invention segments the traditional peptide structure into a novel peptoid architecture where the backbone is chemically modified to resist proteolytic cleavage while side chains retain the aggregation-inhibiting functionality. This segmentation protects the molecular scaffold from degradation while preserving the therapeutic action, achieving both long duration of action and reliable efficacy.
Solution Approach 2:
The patent replaces the naturally occurring peptide backbone (which is mechanically/chemically vulnerable to proteases) with a synthetic peptoid backbone that is inherently resistant to enzymatic degradation. This substitution maintains the essential function of Aβ aggregation inhibition while eliminating the weakness of protease susceptibility, extending compound stability and duration of action.
Data Source
AI summary
Provided herein are peptoids capable of inhibiting or reversing amyloid β (Aβ) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least four monomers with a side-chain having an arylalkyl or aryl group. The peptoid may be achiral. Also provided are methods of using the peptoids to inhibit or reverse aggregation of Aβ and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.